Effects of Chicory on Serum Uric Acid, Renal Function, and GLUT9 Expression in Hyperuricaemic Rats with Renal Injury and In Vitro Verification with Cells

Yong-Nan Jin, Zhi-Jian Lin, Bing Zhang, and Yun-Fei Bai

1Department of Clinical Chinese Pharmacy, School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100029, China
2Department of Integrated TCM and Western Medicine, Yanbian University Hospital, Yanji 133000, China

Correspondence should be addressed to Bing Zhang; Zhangb@bucm.edu.cn

Received 17 September 2018; Revised 14 November 2018; Accepted 22 November 2018; Published 2 December 2018

1. Introduction

Hyperuricaemia (HUA) is a metabolic disorder associated with an abnormally high uric acid level in blood, and HUA is an independent risk factor for chronic kidney disease [1, 2]. As reported in the literature, the risk of developing kidney disease and the risk of worsening renal function increases by 71% and 14%, respectively, for every 1 mg/dl increase in serum uric acid, and the risk of developing new kidney disease is 3 times higher when the serum uric acid level exceeds 9 mg/dl [3].

Approximately, ninety percent of hyperuricaemia cases are caused by insufficient excretion of uric acid [4], and uric acid homeostasis in the body is controlled by the synergistic effect of a number of urate transporters in kidney and intestine. The urate transporters are divided into urate reabsorption transporters and urate excretion transporters. The former includes URAT1 (SLC22A12), OAT4 (SLC22A11), OAT10 (SLC22A13), GLUT9 (SLC2A9), and the latter includes OAT1 (SLC22A6), OAT3 (SLC22A8), MRP2 (ABCC2), MRP4 (ABCC4), NPT1 (SLC17A1), NPT4 (SLC17A3), UAT, and ABCG2 [5–8]. In the kidney, as the urate transporters decrease the reabsorption of uric acid and increase its secretion, they may provide new strategies for the treatment of hyperuricaemia related diseases such as gout, hypertension, diabetes mellitus, coronary heart disease, and chronic kidney disease.

Antihyperuricaemia drugs inhibit or activate these transporters, thereby increasing uric acid excretion in the kidneys to lower blood uric acid levels. Although their pharmacological effect of reducing serum uric acid is clear, these drugs do not effectively delay the progression of renal injury caused by high blood uric acid [9].

Cichorium intybus L., also known as chicory, is a perennial herb belonging to the Asteraceae family. Chicory is regarded as a diuretic and choleretic in Uighur folk medicine and is commonly used in the treatment of jaundice, edema and oliguria [10]. Chicory has some pharmacological effects,
such as anti-diabetic, anti-inflammatory, antioxidant, and anti-hyperlipidaemic effects [11].

In a previous experiment, we found that chicory could decrease serum uric acid levels by inhibiting the activity of xanthine oxidase (XOD), the enzyme that catalyses the generation of uric acid from hypoxanthine and xanthine, and by promoting uric acid excretion by upregulating the mRNA expression of OAT3 in hyperuricaemic rats [12, 13]. However, the effect of chicory on renal uric acid excretion in hyperuricaemic rats with renal injury is unknown, and no studies have been conducted on the effects of chicory on the above-mentioned indicators in hyperuricaemia with renal injury. In addition, it is considered that kidney is responsible for the excretion of 66% of uric acid, and GLUT9 plays an important role in as a high capacity urate transporter in renal uric acid excretion.

Therefore, the objective of this study was to examine the effect of chicory on serum uric acid and renal function in hyperuricaemic rats with renal injury through renal urate excretion and GLUT9 expression based on our previous research. In vitro cell experiments were used to verify the effect of GLUT9 expression on uric acid transport.

2. Materials and Methods

2.1. Drugs. Yeast was purchased from OXOID (UK) and dissolved in purified water (1 g:1 ml) before being given rats. Adenine was purchased from Sigma-Aldrich (USA) and suspended in purified water (80 mg:1 ml) before being given rats. Benzbromarone tablets were purchased from Heumann Pharma GmbH (Germany). The chicory used in the study was authenticated by Professor Yan (Traditional Chinese Medicine Appraisal Teaching and Research Section of Beijing University of Chinese Medicine). Chicory was crushed and ground into powder. The powder was extracted with distilled water (1 g:10 ml) by heating to reflux for 1 h twice. The solution was concentrated by a rotary evaporator after filtering and diluted to different volumes with purified water [13].

2.2. Animals. Sixty male Sprague-Dawley (SD) rats (240-260 g body weight) were purchased from Beijing SPF Laboratory Animal Technology Co., Ltd. (Certificate of Quality: SCXK-2016-0002). The animals were housed in an air-conditioned room where the temperature and humidity were 20-24°C and 45-55%, respectively, with 12 h light-dark cycles. Food and water were provided ad libitum. After 5 days of acclimation, the rats were randomly divided into 5 groups (n=12): control group (CG), hyperuricaemia with renal injury group (MG), benzbromarone group (BEN), and chicory high dosage group (HD-C) or chicory low dosage group (LD-C). Normal rats were used for the other groups intragastrically administered benzibromaron (20 mg·kg⁻¹·d⁻¹) or chicory at a high dosage (15.2 g·kg⁻¹·d⁻¹) or low dosage (6.6 g·kg⁻¹·d⁻¹), and the CG and MG rats were intragastrically administered an equal volume purified water at the same time. The animal experiments lasted 5 weeks. The animal study protocol was approved by the Animal Care and Ethics Committee of Beijing University of Chinese Medicine.

2.3. Sample Collection and Index Detection. Blood samples were collected from the tail tips after 12h of fasting at weeks 1, 3, and 5. The serum was separated and stored at -20°C. The 24-h urine of ten rats per group was collected by the metabolic cage method at weeks 1, 3 and 5. The urinary volume was recorded, and the supernatant was taken and stored at -20°C. Serum uric acid (SUA) and serum creatinine (SCR) levels were measured according to the instructions of a uric acid assay kit (BioSino, China) and CRE assay kit (Nanjing Jiancheng, China), respectively. Additionally, urinary uric acid (UUA) and urinary creatinine (UCr) were measured according to instructions of the same kits. Urinary microalbumin (UMA) was measured according to the microalbumin assay kit (Nanjing Jiancheng, China). The 24-h UUA, 24-h urinary microalbumin and creatinine clearance (CrCl) were calculated by the following equation:

\[
(1) \text{24-h UUA (mg/d)} = \frac{[\text{UUA (µmol/L)}] \times [\text{24-h urine volume (ml/d)}]}{\text{168.11 g/mol} \times 10^{-6}};
\]

\[
(2) \text{24-h UMA (mg/d)} = \frac{[\text{UMA (µmol/L)}] \times [\text{24-h urine volume (ml/d)}]}{\text{10}^{-3}};
\]

\[
(3) \text{CrCl (ml/min)} = \frac{[\text{UCr (µmol/L)}]/[\text{SCR (µmol/L)}] \times \text{[urine volume per minute (ml/min)]}}.
\]

After 5 weeks of treatment, all animals were anaesthetized with 10% chloral hydrate solution (3.5 ml/kg), and blood samples were collected from the abdominal aorta after 12h of fasting. The blood samples were analysed as described above. The upper half of the left kidney was fixed with 4% paraformaldehyde for histological evaluation, and the lower half was preserved at -80°C for western blot and qPCR assays.

2.4. Renal Histological Evaluation. The left kidneys were fixed with 4% buffered paraformaldehyde, dehydrated with 50-100% ethanol and embedded in paraffin. Samples were cut into 3 µm sections and stained with haematoxylin-eosin (HE) for histological observation. The observation and capture were performed with an automated upright microscope system (Olympus BX53, Japan).

2.5. Determination of the Effect of Chicory on GLUT9 mRNA Using qPCR. Total RNA from the kidneys was extracted by Trizol reagent (Thermo Scientific, USA). The concentration of total RNA was measured with a UV-Vis Spectrophotometer Q5000 (Quawell, USA), and the integrity was evaluated by electrophoresis in a 1% agarose gel. The RNA was reverse-transcribed following the manufacturer’s protocol of the Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, USA). Quantitative real-time PCR was performed using iTaq™ Universal SYBR Green Supermix (Bio-Rad, USA) and CFX96™ (Bio-Rad, USA). The forward and reverse primers for GLUT9/SLC2A9 were designed according to the mRNA sequences shown in Table 1 (GenBank NCBI Reference Sequence: NM_00191551.1). The forward and reverse primers for GAPDH were from a literature report.
2.7.1. Cell Culture. The HKC cells were cultured on Transwell polycarbonate membranes for 12 days. The HKC cells (1.0 × 10⁵ cells/ml) in the logarithmic growth phase were seeded in 96-well plates (200 μl/well), complete medium containing the specified concentrations of BEN, Chi, and UA was added to the lower chambers, and the complete medium of the CG contained UA only. Then, 0.5 ml of HBSS was added to the upper chambers. After 30, 60, 90, and 120 min, 300 μl of liquid was taken from the upper chambers, and 300 μl of HBSS was added every time to ensure that the volume of HBSS in the upper chamber was 0.5 ml. The total amount of UA transport at each time period was calculated from the following formula:

\[ \Delta Q = C_n \cdot V_{AP} + C_t \cdot V \]  

\( \Delta Q \) is the total amount of UA transport at each time period; \( C_n \) is the concentration of UA in the liquid collected at the previous time point; \( V_{AP} \) is the upper chamber volume.

First, the culture medium in both the upper and lower chambers was removed, and the HKC cell monolayer was washed twice with 37°C HBSS. Complete medium (1.5 ml) containing the specified concentrations of BEN, Chi, and UA was added to the lower chambers, and the complete medium of the CG contained UA only. Then, 0.5 ml of HBSS was added to the upper chambers. After 30, 60, 90, and 120 min, 300 μl of liquid was taken from the upper chambers, and 300 μl of HBSS was added every time to ensure that the volume of HBSS in the upper chamber was 0.5 ml. The total amount of UA transport at each time period was calculated from the following formula:

\[ \Delta Q = C_n \cdot V_{AP} + C_t \cdot V \]  

Derivation of the Effect of Chicory on GLUT9 Protein Using Western Blotting. The HKC cells were incubated in complete medium containing UA, BEN, and Chi for 24 h, and then the cells were collected and lysed by RIPA (Solarbio, China). The total protein was extracted and denatured by heating in a water bath for 10 min. The proteins (5 μg) were separated by 10% SDS-PAGE under a constant current of 300 mA for 90 min. The next procedures, including blocking with milk, primary and secondary antibody incubation, protein blot visualization, and quantification, were the same as described in Section 2.6.

2.7.4. Determination of the Effect of Chicory on the Transport Ability of GLUT9 Using the Transwell Assay and HPLC. HKC cells (1.0 × 10⁵ cells/ml) in the logarithmic growth phase were added to the upper chamber (500 μl/well) of 12-well Transwell plates (0.4 μm, Corning, USA), and complete medium was added to the lower chamber (1.5 ml/well). The HKC cells were cultured on Transwell polycarbonate membranes for 12 days. The transepithelial electrical resistance (TEER) of the cell monolayer was measured by an Epithelial Volt-Ohm Meter (Millicell ERS-2, Millipore, USA), and the culture medium was replaced every 2 days. The UA transport experiment began when the TEER gradually increased and tended to be stabilized.

First, the culture medium in both the upper and lower chambers was removed, and the HKC cell monolayer was washed twice with 37°C HBSS. Complete medium (1.5 ml) containing the specified concentrations of BEN, Chi, and UA was added to the lower chambers, and the complete medium of the CG contained UA only. Then, 0.5 ml of HBSS was added to the upper chambers. After 30, 60, 90, and 120 min, 300 μl of liquid was taken from the upper chambers, and 300 μl of HBSS was added every time to ensure that the volume of HBSS in the upper chamber was 0.5 ml. The total amount of UA transport at each time period was calculated from the following formula:

\[ \Delta Q = C_n \cdot V_{AP} + C_t \cdot V \]  

\( \Delta Q \) is the total amount of UA transport at each time period; \( C_n \) is the concentration of UA in the liquid collected at the previous time point; \( V_{AP} \) is the upper chamber volume.
(0.5 ml); $C_i$ is the concentration of UA in the liquid collected at each time point; $V$ is the volume of liquid collected from the upper chamber every time (0.3 ml).

The liquid samples were filtered through a 0.45 $\mu$m filter, and the UA content in each sample was determined using an Agilent 1100 Series HPLC system (Agilent Technologies, USA) equipped with a photodiode array detector. An Agilent Eclipse XDB-C$_{18}$ (5 $\mu$m, 250 mm $\times$ 4.6 mm, Agilent, USA) column was used with a mobile phase consisting of solvents A (6%; methanol) and B (94%; water containing 0.2% acetic acid); the flow rate was 1.0 ml/min. The column temperature was maintained at 30 $^\circ$C, and the detection wavelength was set at 288 nm. The sample volume was 20 $\mu$l.

2.8. Statistical Analysis. Statistical analyses were conducted by SPSS 20.0 software. All data were expressed as the mean ± standard deviation (SD). The statistical analysis was performed using analysis of variance (ANOVA) followed by Dunnett’s multiple range tests to determine levels of significance. $AP$-value $< 0.05$ was considered statistically significant.

3. Results

3.1. Effect of Chicory on Serum Uric Acid in Hyperuricaemic Rats with Renal Injury. As shown in Figure 1, the serum uric acid (SUA) levels of the model group (MG) were increased significantly at week 3 and week 5 ($P < 0.05, P < 0.01$) compared with those in the control group (CG). Compared with those in the MG, the SUA levels decreased significantly at week 3 and week 5 in the benzbromarone group (BEN) and the low dosage of chicory group (LD-C) ($P < 0.05$) and decreased significantly at week 5 in the high dosage of chicory group (HD-C) ($P < 0.05$) (Table S1).

3.2. Effect of Chicory on Serum Creatinine in Hyperuricaemic Rats with Renal Injury. As shown in Figure 2, the serum creatinine (SCr) levels of the MG were increased significantly at week 3 and week 5 ($P < 0.01$) compared with those in the CG. Compared with those in the MG, the SCr level increased significantly at week 3 in the BEN ($P < 0.01$) and decreased significantly in the HD-C and LD-C week 3 and week 5 ($P < 0.05, P < 0.01$) (Table S2).

3.3. Effect of Chicory on 24-h Urine Volume in Hyperuricaemic Rats with Renal Injury. As shown in Figure 3, the 24-h urine volume was significantly higher at weeks 1, 3, and 5 ($P < 0.01$) in the MG than in the CG. Compared with the volume in the MG, the volume at the same time point was significantly lower in the BEN and LD-C ($P < 0.05, P < 0.01$), and the volume in the HD-C was significantly lower at week 3 and week 5 ($P < 0.01, P < 0.05$) (Table S3).

3.4. Effect of Chicory on 24-h Urinary Uric Acid Excretion in Hyperuricaemic Rats with Renal Injury. As shown in Figure 4, the 24-h urinary uric acid (UUA) excretion levels at week 3 and week 5 were significantly lower ($P < 0.05$) in the MG than in the CG. Compared with those in the MG, the 24-h UUA excretion levels of the BEN were
 Evidence-Based Complementary and Alternative Medicine

3.5. Effect of Chicory on Creatinine Clearance in Hyperuricaemic Rats with Renal Injury. As shown in Figure 5, the creatinine clearance (CrCl) levels of the MG were decreased significantly at week 3 and week 5 (P < 0.05, P < 0.01) compared with those of the CG. The CrCl levels of the BEN, HD-C, and LD-C were significantly higher at the same time (P < 0.05, P < 0.01) than that in the MG (Table S5).

3.6. Effect of Chicory on 24-h Urinary Microalbumin Level in Hyperuricaemic Rats with Renal Injury. As shown in Figure 6, the 24-h urinary microalbumin (UMA) level of the MG increased significantly at weeks 1, 3, and 5 (P < 0.01) compared with that in the CG. Compared with the MG, all treatment groups showed a pronounced decrease (P < 0.05, P < 0.01), except for the BEN at week 5 (Table S6).

3.7. Effect of Chicory on Renal Histopathology in Hyperuricaemic Rats with Renal Injury. As shown in Figures 7 and 8, haematoxylin and eosin (HE) stained kidney sections from the CG showed normal histological structures for the glomerulus, proximal convoluted tubules and distal convoluted tubules under light microscopy. There was tubular ectasia, and urate crystals were deposited in the tubules, with considerable inflammatory cell infiltration and focal fibrosis in the MG. The changes in tissue morphology, such as inflammatory cell infiltration, renal tubular ectasia and interstitial fibrosis, in the BEN, HD-C, and LD-C, were not evident as in the MG.

3.8. Effect of Chicory on Kidney GLUT9 mRNA Expression in Hyperuricaemic Rats with Renal Injury. Figure 9 shows that the GLUT9 (SLC2A9) mRNA expression levels were not different between any two groups (Table S7).

3.9. Effect of Chicory on Kidney GLUT9 Protein Expression in Hyperuricaemic Rats with Renal Injury. As shown in Figure 10, the kidney GLUT9 protein expression in the MG increased significantly (P < 0.01) compared with that in the CG, and its expression in the BEN, HD-C, and LD-C decreased significantly (P < 0.01, P < 0.05) compared with that in the MG (Table S8).

3.10. Effect of Chicory on the Proliferation of HKC Cells Determined Using the MTT Assay. As shown in Tables 2–4, UA concentrations greater than or equal to 400 μmol/L significantly promoted the proliferation of HKC cells at 24 h and 48 h (P < 0.05, P < 0.01). Benz bromarone inhibited the proliferation of HKC cells, 200 μmol/L significantly inhibited the proliferation (P < 0.05) at 24 h, and 50 μmol/L significantly inhibited the proliferation at 48 h (P < 0.05). Chicory had no significant effect on HKC proliferation in the concentration range of 100–800 μg/ml at 24 h.

3.11. Effect of Chicory on HKC Cells GLUT9 Protein Expression. As shown in Figure 11, the HKC cells GLUT9 protein...
Figure 7: Glomerulus (HE, ×10 objective lens). (a) Control group; (b) hyperuricaemia with renal injury group; (c) group treated with benzbromarone; (d) group treated with the high dosage of chicory; (e) group treated with the low dosage of chicory.

Figure 8: Renal tubule (HE, ×10 objective lens). (f) Control group; (g) hyperuricaemia with renal injury group; (h) group treated with benzbromarone; (i) group treated with the high dosage of chicory; (j) group treated with the low dosage of chicory.

Figure 9: Effect of chicory on kidneys GLUT9 mRNA expression in hyperuricaemic rats with renal injury examined by RT-PCR.

Table 2: Comparison of HKC cells proliferation ability at 24 h and 48 h with various concentrations of UA (X±s, n=6).

| UA (μmol/L) | 24 h | 48 h |
|------------|------|------|
| 0 (control group) | 0.2959 ± 0.0267 | 0.4022 ± 0.0333 |
| 100 | 0.3121 ± 0.0242 | 0.4223 ± 0.0203 |
| 200 | 0.3257 ± 0.0367 | 0.4406 ± 0.0345 |
| 400 | 0.3389 ± 0.0245* | 0.4522 ± 0.0273* |
| 600 | 0.3528 ± 0.0394* | 0.4851 ± 0.0375** |
| 800 | 0.3742 ± 0.0263** | 0.4963 ± 0.0294** |

Notes: ∗P<0.05, ∗∗P<0.01 vs CG.

expression increased significantly (P<0.05) when it stimulated with 400 μmol/L UA for 24 h, and its expressions decreased significantly (P<0.01 or P<0.05) when it stimulated with 50 μmol/L BEN or 200 μg/ml Chi at the same time (Table S9).

3.12. Effect of Chicory on the Ability of Monolayer HKC Cells to Transport UA. As shown in Figure 12(a), the resistance of the monolayer of HKC cells on the Transwell polycarbonate membrane increased gradually, reached the peak (about 200Ω•cm²) and then tended to be stable at 14-16 days. The concentration of UA standard substances in HBSS collected from the upper portions of the Transwell chamber at 30, 60, 90 and 120 min was determined by HPLC, and the amounts

Figure 10: Effect of chicory on kidneys GLUT9 protein expression in hyperuricaemic rats with renal injury examined by western blotting.

with 50 μmol/L BEN or 200 μg/ml Chi at the same time (Table S9).
Table 3: Comparison of HKC cells proliferation ability at 24 h and 48 h with various concentrations of benzbromarone (±s, n=6).

| Benzbroromarone (μmol/L) | 24h      | 48h        |
|--------------------------|----------|------------|
| 0 (control group)        | 0.3065 ± 0.0216 | 0.4209 ± 0.0267 |
| 12.5                     | 0.2992 ± 0.0297 | 0.4092 ± 0.0360 |
| 25                       | 0.3043 ± 0.0305 | 0.3768 ± 0.0364∗ |
| 50                       | 0.2790 ± 0.0237 | 0.3370 ± 0.0381∗∗ |
| 100                      | 0.2756 ± 0.0347 | 0.3377 ± 0.0352∗∗ |
| 200                      | 0.2551 ± 0.0384∗ | 0.3177 ± 0.0426∗∗ |

Notes. ∗P<0.05, ∗∗P<0.01 vs CG.

Table 4: Comparison of HKC cells proliferation ability at 24 h and 48 h with various concentrations of chicory (±s, n=6).

| Chicory (μg/ml) | 24h      | 48h        |
|-----------------|----------|------------|
| 0 (control group)        | 0.2859 ± 0.0230 | 0.4097 ± 0.0433 |
| 100              | 0.2858 ± 0.0188 | 0.3783 ± 0.0464 |
| 200              | 0.2657 ± 0.0240 | 0.3724 ± 0.0501 |
| 400              | 0.2644 ± 0.0354 | 0.3611 ± 0.0459 |
| 600              | 0.2726 ± 0.0221 | 0.3408 ± 0.0317∗ |
| 800              | 0.2602 ± 0.0475 | 0.3421 ± 0.0483∗ |

Notes. ∗P<0.05.

Figure 11: GLUT9 protein expression in HKC by western blotting.

Figure 12: Transmembrane transport of UA from standard solution (UA (μg/ml)) and control group sample at 3.7 min. (UA (μg/ml)) of UA transferred from the lower chambers to the upper chambers were calculated every 30 min (Table S10).

The results showed in Figure 12(b) that transmembrane transport of UA to monolayer HKC cells was reduced after treatment with benzbromarone and chicory. When the concentrations of benzbromarone and chicory were in the range of 25-100 μmol/L and 100-400 μg/ml, respectively, the transmembrane transport of UA decreased with increasing drug concentration.

Figure 12(c) is the one peak of UA from standard solution. The peak appeared at 3.7 min, and the UA concentration is 16.810 μg/ml. Figure 12(d) is the peak of UA from control group sample at 3.7 min.

4. Discussion

In this study, the effect of chicory on serum uric acid (SUA), renal function and GLUT9 expression in the pathological state of hyperuricaemia rats with renal injury was investigated. Hyperuricaemia with renal injury was induced in rats by intragastric administration of yeast (15 g⋅kg⁻¹⋅d⁻¹) and adenine (80 mg⋅kg⁻¹⋅d⁻¹). The purine in yeast generates uric acid (UA) by the action of XOD and other enzymes in vivo. However, most mammals have uricase, which can catalyse UA oxidation to produce allantoin. Allantoin can dissolve in water and can be excreted from the kidney without being absorbed by renal tubules. Therefore, yeast is commonly used in combination with other agents, such as ethambutol and potassium oxonate, to induce hyperuricaemia in rats and mice [14–16]. For this purpose, we chose adenine, which is a nitrogenous heterocyclic purine compound. Adenine can increase phosphoribosyl pyrophosphate and glutamine in vivo to promote purine metabolism. On the other hand, adenine can become 2,8-dihydroxy adenine, which is extremely insoluble in water and crystallizes in the renal tubules, leading to chronic renal failure [17].

As expected, the model group (MG) displayed hyperuricaemia and renal function injury from week 3 to week 5. The levels of SUA and creatinine increased in the MG, and the 24-h urine volume also increased.

Creatinine clearance (CrCl) is an indicator that can reflect renal function more accurately and sensitively than serum creatinine [18], and the endogenous creatinine clearance rate is a sensitive index for evaluating impaired glomerular filtration. The results showed that, in the MG, CrCl decreased to 72.7% and 42.3% at week 3 and week 5, respectively. At the
same time, for treatment with benzbromarone, high dosage and low dosage of chicory, the CrCl reached 114.3%, 116.0%, and 124.9% at week 3 and 91.2%, 94.6%, and 90.1% at week 5, respectively. This finding indicated that benzbromarone and chicory can alleviate the kidney damage caused by yeast and adenine in rats.

As shown with haematoxylin and eosin (HE) staining, the numbers of glomeruli in the high dosage and low dosage of chicory groups were greater than those in the model and benzbromarone groups, and the renal tubular expansion was less than that in the model and benzbromarone groups. These changes support the protective effect of chicory on renal function.

Excretion of UA is mainly determined by the balance between renal reabsorption and secretion, and the role of various urate transporters has been debated [8]. Usually, GLUT9, URAT1, OAT1, and OAT3 are the main transporters regulating renal urate handling, while ABCG2 appears to regulate intestinal transport [19]. For example, Vibha Bhatnagar et al. pointed out that Chronic Renal Insufficiency Cohort data showed that GLUT9 played a much less significant role than ABCG2 in this subset of patients with CKD [20]. Similarly, Hirofumi Yano et al. observed that serum UA level did not increase despite the decrease in renal UA excretion in the 5/6 nephrectomy rats model [21]. These studies in patients of CKD and rodent animals showed that renal urate transport was affected during CKD, and ABCG2 may play a compensatory role and compensate for the extra-renal excretion.

In addition, GLUT9 (SLC2A9) is known to transport glucose or fructose until Doblado and Moley reported that GLUT9 may transport not only fructose but also urate [22–24], and this study is focused on GLUT9 and renal urate excretion. At present, GLUT9 is thought to be a high capacity and low affinity urate transporter [25–27]. GLUT9 is located on the basolateral membrane of renal tubular epithelial cells. Hamajima et al. [28], through the analysis of candidate genes from 5024 healthy Japanese individuals, found a significant correlation between SLC2A9 rs11722228 and the level of SUA. Research from Wang M and Yang H showed that SUA was reduced in hyperuricaemic mice and that renal UA excretion was promoted in hyperuricaemic rats when the expression of GLUT9 was inhibited [29, 30].
As shown in the qPCR and western blot results, there was no significant change in GLUT9 mRNA expression in each group of kidney tissues. However, GLUT9 protein expression in the kidney increased markedly to 128.3% in hyperuricaemic rats with renal injury, and the expression levels decreased to 77.8%, 81.2%, and 84.3%, respectively, when the animals were treated with benzbromarone, high dosage chicory and low dosage chicory. This result indicated that chicory could inhibit the expression of GLUT9 protein in the kidneys of hyperuricaemic rats with renal injury. As a result, the UA reabsorption in the renal tubules is reduced, and the UA excretion by renal tubules is increased. Therefore, chicory plays a role in reducing SUA levels.

Cell experiments were performed in vitro to further verify that the effect of chicory on reducing UA is related to the regulation of GLUT9 protein expression. Benzbromarone was used as an inhibitor to inhibit GLUT9 in HKC cells, and the effects of chicory on protein expression and the ability of monolayer HKC cells to transport UA were evaluated to verify that chicory lowers SUA by regulating GLUT9 protein expression.

HKC cells are a group of cells that are mostly composed of normal human proximal tubular epithelial cells. HKC cells are widely used in pharmacological and toxicological experiments [31, 32]. GLUT9 is mainly distributed on the tubular apical membrane of the renal tubule. Protein was extracted from HKC cells and incubated with GLUT9 (SLC2A9) primary antibody, and its protein band was located at 62 kDa. After 24 h of UA stimulation, the expression increased 26.7%, benzbromarone decreased the expression to 21.3%, and chicory (200 μg/ml) decreased the expression to 18.1%. The western blot results of the HKC cells were consistent with the results of the kidney tissue.

The effect of chicory on the expression of GLUT9 protein has been clarified. To further observe the effect of chicory on GLUT9 function, a Transwell assay was used for UA transport experiments. Literature reports indicate that Tranilast can inhibit urate transport through URAT1 and GLUT9 in a reversible, noncompetitive manner [33] and that benzbromarone can also inhibit GLUT9 and URAT1 [34]. Therefore, the decrease in UA transport in the Transwell assay is not only caused by changes in GLUT9 expression levels but also may be affected by changes in the expression levels of other uric acid transporters, such as URAT1. However, the GLUT9 protein band was incubated with a specific primary antibody against GLUT9 (SLC2A9), and chicory reduced the GLUT9 protein expression on HKC cells induced by UA stimulation. Therefore, combining the two results indicate that chicory can inhibit the expression of GLUT9 protein in renal tubules and that this inhibition affects the ability of GLUT9 to transport UA.

Finally, knockout mice are used in the research of urate transporters at present. It is reported that OAT1 and OAT3 knockout mice without obvious histological or anatomic abnormalities, and they are similar to their wild-type counterparts with respect to metabolic parameters. Thus the knockout mice could use assessment of renal transport of urate and other organic anions [8]. Therefore, our further research may be to select gene knockout rats or mice to verify the conclusions of this study.

5. Conclusion

The study indicated that chicory lowered serum uric acid levels and alleviated renal function in hyperuricaemic rats with renal injury. In vitro and in vivo biochemical experiments showed that chicory acts on the renal uric acid transporter GLUT9 and down regulates its protein expression level as a mechanism for reducing uric acid. The experiment showed that the chicory had a better effect than benzbromarone in delaying the development of renal function damage caused by adenine in model animals, indicating the possibility of using chicory as an alternative to alleviating renal damage in hyperuricaemia.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank the Animal Experimental Center of Beijing University of Chinese Medicine for its support to this project. This research is funded by financially supported by the National Natural Science Foundation of China (no. 81673618), Beijing Natural Science Foundation (no. 7162117), and National Science and Technology Major Projects for "Major New Drugs Innovation and Development" (no. 2017ZX09301024).

Supplementary Materials

Table S1: The effect of chicory on SUA in hyperuricaemic rats with renal injury. Table S2: The effect of chicory on SCR in hyperuricaemic rats with renal injury. Table S3: The effect of chicory on 24-h urine volume in hyperuricaemic rats with renal injury. Table S4: The effect of chicory on 24-h UUA excretion in hyperuricaemic rats with renal injury. Table S5: The effect of chicory on CrCl in hyperuricaemic rats with renal injury. Table S6: The effect of chicory on 24-h SCr in hyperuricaemic rats with renal injury. Table S7: The effect of chicory on kidneys GLUT9 mRNA expression in hyperuricaemic rats with renal injury. Table S8: The effect of chicory on kidneys GLUT9 protein expression in hyperuricaemic rats with renal injury. Table S9: The effect of chicory on GLUT9 protein expression in HKC cells. Table S10: The changes of TEER values in HKC cell monolayer (Supplementary Materials). (Supplementary Materials)
References

[1] B. Lin, L. Shao, Q. Luo et al., "Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province, Eastern China," BMC Nephrology, vol. 15, no. 1, p. 36, 2014.

[2] R. P. Obermayr, C. Temml, G. Gunjahr, M. Knechtelsdorfer, R. Oberbauer, and R. Klauser-Braun, "Elevated uric acid increases the risk for kidney disease," Journal of the American Society of Nephrology, vol. 19, no. 12, pp. 2407–2413, 2008.

[3] S.-W. Xiang, S.-C. Lai, and Y.-H. Meng, "Clinical study on modified sanmiao powder in treating chronic uric acid nephropathy," Chinese Journal of Integrated Traditional and Western Medicine, vol. 29, no. 11, pp. 979–981, 2009.

[4] F. Perez-Ruiz, N. Dalbeth, and T. Bardin, "A review of uric acid, crystal deposition disease, and gout," Advances in Therapy, vol. 32, no. 1, pp. 31–41, 2015.

[5] A. Enomoto, H. Kimura, A. Chairoungdua et al., "Molecular identification of a renal urate-anion exchanger that regulates blood urate levels," Nature, vol. 417, no. 6867, pp. 447–452, 2002.

[6] C. E. Lopez-Nieto, G. You, K. T. Bush, E. J. G. Barros, D. R. Beier, and S. K. Nigam, "Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney," The Journal of Biological Chemistry, vol. 272, no. 10, pp. 6471–6478, 1997.

[7] V. Vitart, I. Rudan, C. Hayward et al., "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout," Nature Genetics, vol. 40, no. 4, pp. 437–442, 2008.

[8] S. A. Eraly, V. Vallon, T. Rieg et al., "Multiple organic anion transporters contribute to net renal excretion of uric acid," Physiological Genomics, vol. 33, no. 2, pp. 180–192, 2008.

[9] Y. Guo, Q. Jiang, D. Gui, and N. Wang, "Chinese herbal formulas Si-Wu-Tang and Er-Miao-San synergistically ameliorated hyperuricemia and renal impairment in rats induced by adenine and potassium oxonate," Cellular Physiology and Biochemistry, vol. 37, no. 4, pp. 1491–1502, 2015.

[10] Chinese Pharmacopoeia Commission, People’s Republic of China Pharmacopoeia 2015 Edition, China Medical Science and Technology Press, Beijing, China, 2015.

[11] A. Hosomi, T. Nakanishi, T. Fujita, and I. Tamai, "Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2," PLoS ONE, vol. 7, no. 2, p. e36456, 2012.

[12] L. Y. Li, Z. J. Lin, and B. Zhang, "Effect of Chinese herb chicyrin on renal organic anion transporter OAT3-LIKE of hyperuricemia quails," Traditional Chinese Drug Research and Clinical Pharmacology, vol. 26, no. 3, pp. 284–289, 2015.

[13] X.-J. Wang, Z.-J. Lin, B. Zhang et al., "Molecular docking analysis of xanthine oxidase inhibition by constituents of cichory," Zhongguo Zhongyao Zazhi, vol. 40, no. 19, pp. 3818–3825, 2015.

[14] J. Chen, J. Zhou, S. Wei, Z. Xie, C. Wen, and G. Xu, "Effect of a traditional Chinese medicine prescription Quzhouotongbi decoction on hyperuricemia model rats studied by using serum metabolomics based on gas chromatography–mass spectrometry," Journal of Chromatography B, vol. 1026, pp. 272–278, 2015.

[15] D. Xilifu, A. Abudula, N. Rehemu, L. Zhao, X. Zhou, and X. Zhang, "Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction," Experimental and Therapeutic Medicine, vol. 8, no. 6, pp. 1683–1688, 2014.

[16] W.-F. Sun, X.-X. Zhang, F.-Y. Sun et al., "MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction," Chinese Journal of Integrative Medicine, vol. 17, no. 1, pp. 35–42, 2011.

[17] G. Yang, S. Huang, and J. Li, "Compare the rat model of hyperuricemia made by adenine and oxonic acid," Laboratory Animal Science, vol. 8, pp. 23–36, 2011.

[18] S. Ikegawa, K.-I. Matsuoka, T. Inomata et al., "Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation," International Journal of Hematology, vol. 107, pp. 568–577, 2018.

[19] S. K. Nigam and V. Bhatnagar, "The systems biology of uric acid transporters," Current Opinion in Nephrology and Hypertension, vol. 27, no. 4, pp. 305–313, 2018.

[20] V. Bhatnagar, E. L. Richard, W. Wu et al., "Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: Potential role of remote sensing and signaling," Clinical Kidney Journal, vol. 9, no. 3, pp. 444–453, 2016.

[21] H. Yano, Y. Tamura, K. Kobayashi, M. Tanemoto, and S. Uchida, "Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease," Clinical and Experimental Nephrology, vol. 18, no. 1, pp. 50–55, 2014.

[22] K. Ebert, M. Ludwig, K. E. Geillinger et al., "Reassessment of GLUT7 and GLUT9 as Putative Fructose and Glucose Transporters," Journal of Membrane Biology, vol. 250, no. 2, pp. 171–182, 2017.

[23] J. E. Phay, H. B. Hussain, and J. F. Moley, "Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9)," Genomics, vol. 66, no. 2, pp. 217–220, 2000.

[24] M. Doblando and K. H. Moley, "Facilitative glucose transporter 9, a unique hexose and urate transporter," American Journal of Physiology-Endocrinology and Metabolism, vol. 297, no. 4, pp. E831–E835, 2009.

[25] N. Anzai, K. Ichida, P. Jutabha et al., "Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URAT1 (SLC2A9) in humans," The Journal of Biological Chemistry, vol. 283, no. 40, pp. 26834–26838, 2008.

[26] S. Bibert, S. K. Hess, D. Firso et al., "Mouse GLUT9: Evidences for a urate uniporter," American Journal of Physiology-Renal Physiology, vol. 297, no. 3, pp. F612–F619, 2009.

[27] B. Clémenson, B. P. Lüscher, M. Fine et al., "Expression, purification, and structural insights for the human uric acid transporter, GLUT9, using the xenopus laevis oocytes system," PLoS ONE, vol. 9, no. 10, p. e108852, 2014.

[28] N. Hamajima, R. Okada, S. Kawai et al., "Significant association of serum uric acid levels with SLC2A9 rs1722228 among a Japanese population," Molecular Genetics and Metabolism, vol. 103, no. 4, pp. 378–382, 2011.

[29] M. Wang, J. Zhao, N. Zhang, and J. Chen, "Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice," Biomedicine & Pharmacotherapy, vol. 83, pp. 975–988, 2016.

[30] H. Yang, L. Gao, Y. Niu et al., "Mangiferin inhibits renal urate reabsorption by modulating urate transporters in experimental hyperuricemia," Biological & Pharmaceutical Bulletin, vol. 38, no. 10, pp. 1591–1598, 2015.

[31] Y. Man, H. Rui, Y. Chen et al., "Aristolochic acid-induced autophagy promotes epithelial-to-myofibroblast transition in human renal proximal tubule epithelial cells," Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 9596256, 13 pages, 2017.
[32] D. Felsen, B. J. Diaz, J. Chen et al., “Pressure and stretch differentially affect proliferation of renal proximal tubular cells,” *Physiological Reports*, vol. 5, no. 17, p. e13346, 2017.

[33] A. K. Mandal, A. Mercado, A. Foster, K. Zandi-Nejad, and D. B. Mount, “Uricosuric targets of tranilast,” *Pharmacology Research and Perspectives*, vol. 5, no. 2, Article ID e00291, 2017.

[34] Y. W. Liu and W. F. Sun, “Research progress of uric acid transporter related protein SLC2A9/GLUT9,” *Guangdong Medical Journal*, vol. 34, no. 1, pp. 2261–2263, 2013.